JP2021534766A5 - - Google Patents

Info

Publication number
JP2021534766A5
JP2021534766A5 JP2021510129A JP2021510129A JP2021534766A5 JP 2021534766 A5 JP2021534766 A5 JP 2021534766A5 JP 2021510129 A JP2021510129 A JP 2021510129A JP 2021510129 A JP2021510129 A JP 2021510129A JP 2021534766 A5 JP2021534766 A5 JP 2021534766A5
Authority
JP
Japan
Prior art keywords
recombinant aav
capsid protein
promoter
item
virus particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534766A (ja
JP7688572B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049157 external-priority patent/WO2020047472A1/en
Publication of JP2021534766A publication Critical patent/JP2021534766A/ja
Publication of JP2021534766A5 publication Critical patent/JP2021534766A5/ja
Priority to JP2024174226A priority Critical patent/JP2025004107A/ja
Application granted granted Critical
Publication of JP7688572B2 publication Critical patent/JP7688572B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510129A 2018-08-30 2019-08-30 ガラクトース血症の処置のための遺伝子治療 Active JP7688572B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174226A JP2025004107A (ja) 2018-08-30 2024-10-03 ガラクトース血症の処置のための遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725225P 2018-08-30 2018-08-30
US62/725,225 2018-08-30
PCT/US2019/049157 WO2020047472A1 (en) 2018-08-30 2019-08-30 Gene therapy for the treatment of galactosemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174226A Division JP2025004107A (ja) 2018-08-30 2024-10-03 ガラクトース血症の処置のための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2021534766A JP2021534766A (ja) 2021-12-16
JP2021534766A5 true JP2021534766A5 (cg-RX-API-DMAC7.html) 2022-09-06
JP7688572B2 JP7688572B2 (ja) 2025-06-04

Family

ID=69643062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510129A Active JP7688572B2 (ja) 2018-08-30 2019-08-30 ガラクトース血症の処置のための遺伝子治療
JP2024174226A Withdrawn JP2025004107A (ja) 2018-08-30 2024-10-03 ガラクトース血症の処置のための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174226A Withdrawn JP2025004107A (ja) 2018-08-30 2024-10-03 ガラクトース血症の処置のための遺伝子治療

Country Status (11)

Country Link
US (1) US20210299275A1 (cg-RX-API-DMAC7.html)
EP (1) EP3844294A4 (cg-RX-API-DMAC7.html)
JP (2) JP7688572B2 (cg-RX-API-DMAC7.html)
KR (1) KR102997951B1 (cg-RX-API-DMAC7.html)
CN (2) CN112867798A (cg-RX-API-DMAC7.html)
AU (2) AU2019328573A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003174A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110290A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002041A (cg-RX-API-DMAC7.html)
SG (1) SG11202101819QA (cg-RX-API-DMAC7.html)
WO (1) WO2020047472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277270B2 (en) 2018-03-16 2025-05-01 Res Inst Nationwide Childrens Hospital Increasing tissue-specific gene delivery through capsid modification
WO2023279108A1 (en) * 2021-07-01 2023-01-05 Bridgebio Gene Therapy Research, Inc. Gene therapy for galactosemia
AU2022340823A1 (en) * 2021-09-01 2024-04-18 Emory University Adeno-associated vectors and virions to treat galactosemia and methods of use and manufacture
PE20241891A1 (es) * 2021-09-01 2024-09-19 Jaguar Gene Therapy Llc Vectores y viriones adenoasociados para tratar la galactosemia y metodos de uso y fabricacion
WO2024211480A2 (en) * 2023-04-05 2024-10-10 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106381A1 (en) * 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2002308540A1 (en) * 2001-05-01 2002-11-11 Genstar Therapeutics Corp. Mini-adenoviral vector and methods of using same
WO2003088899A2 (en) * 2002-04-05 2003-10-30 The Children's Hospital Of Philadelphia Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US20060053500A1 (en) * 2004-05-28 2006-03-09 Univ. of Pittsburgh of the Commonwealth System of Higher Education, Office of Technology Management Modification of sugar metabolic processes in transgenic cells, tissues and animals
JP5670330B2 (ja) * 2008-08-07 2015-02-18 ハー マジェスティ ザ クイーン イン ライト オブ カナダ アズ リプリゼンテド バイ ザ ミニスター オブ ヘルスHER MAJESTY THE QUEEN IN RIGHTOF CANADA as represented by THE MINISTER OF HEALTH 最適化したプロモーター配列
US20110223635A1 (en) * 2008-08-11 2011-09-15 Karl Deisseroth Method and Composition for Controlling Gene Expression
SG10201604810UA (en) * 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
US10688285B2 (en) * 2015-01-30 2020-06-23 The Regents Of The University Of California Spinal subpial gene delivery system
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
US11253612B2 (en) * 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
US11001861B2 (en) * 2016-05-18 2021-05-11 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
US10873929B2 (en) * 2016-11-06 2020-12-22 Lg Electronics Inc. Method and user equipment for transmitting random access signals, and method and base station for receiving random access signals

Similar Documents

Publication Publication Date Title
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
JP2022060228A5 (cg-RX-API-DMAC7.html)
JP2023514242A5 (cg-RX-API-DMAC7.html)
US20240376498A1 (en) Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1
JP2022524434A5 (cg-RX-API-DMAC7.html)
US12359219B2 (en) Transgene cassettes designed to express a human MECP2 gene
AU2016347887A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
JP2022551744A5 (cg-RX-API-DMAC7.html)
JP2022525302A5 (cg-RX-API-DMAC7.html)
US12534741B2 (en) Compositions and methods for treatment of neurological disorders
JP2025500347A5 (cg-RX-API-DMAC7.html)
US20250283111A1 (en) Recombinant adeno-associated viral vector for gene delivery
JP2023537358A5 (cg-RX-API-DMAC7.html)
JP2023520763A5 (cg-RX-API-DMAC7.html)
EP4627093A1 (en) Adeno-associated viral vectors for proper packaging of repetitive elements
JP2023542131A5 (cg-RX-API-DMAC7.html)
JP2023542132A5 (cg-RX-API-DMAC7.html)
WO2024220719A1 (en) Modified aav capsids for gene delivery
US12480098B1 (en) Adeno-associated virus variant
WO2024163335A2 (en) Pten gene therapy vectors and uses thereof
RU2022111695A (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение
KR20260057323A (ko) 아데노연관바이러스 변이체
CN118019855A (zh) Slc13a5基因治疗载体及其用途
RU2023109483A (ru) Невирусные днк-векторы и варианты их применения для экспрессии терапевтического средства на основе фактора viii (fviii)